All information you are about to see is related to a specific selected market, including the products’ portfolio, and therefore comply to different local regulations.

Our financial data in facts & figures

OUR GROUP REVENUES

EBITDA (2022)

77.2 (18.7% of turnover)

EBIT (2022)

51.7 (12.5% of turnover)

NET RESULT (2022)

37.8 (9.2% of turnover)

Related Documents

Discover more

OUR GROUP FIGURES BY FOCUS AREA (€ Millions, 2022)

Net revenue

412,1

€ Millions

153,9 € Millions

JOINT CARE

82,2 € Millions

EYE CARE

47,5 € Millions

SKIN CARE

34,3 € Millions

CORTICOSTEROIDS

5,1 € Millions

ACTIVE SUBSTANCES

89,0 € Millions

OTHER

OUR FIGURES BY PRODUCT CATEGORY (2022)

42 %

PRESCRIPTION DRUGS

39 %

MEDICAL DEVICES

5 %

VACCINES

14 %

OTHER

OUR GROUP FIGURES BY GEOGRAPHICAL AREA (€ Millions, 2022)

Net revenue

410,1

€ Millions

216,2 € Millions

ITALY

112,7 € Millions

EUROPE

58,4 € Millions

USA

15,8 € Millions

MENA

7,0 € Millions

RoW

OUR GROUP

GOVERNANCE

Find out more